Search is Powered by Google
HIV / AIDS News

Boehringer To Reduce Price Of Antiretroviral Nevirapine In Low-, Middle-Income Countries, Official Says

Main Category: HIV / AIDS
Also Included In: Pharma Industry / Biotech Industry
Article Date: 18 May 2007 - 1:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

German pharmaceutical company Boehringer Ingelheim will reduce the price of its antiretroviral drug nevirapine, sold under the brand name Viramune, by 50% and 90% in low- and middle-income countries, respectively, Alessandro Banchi, chair of the company's managing board, said recently in an interview, the Financial Times reports (Jack, Financial Times, 5/15). Nevirapine -- a low-cost medication that is used as a standard method of reducing mother-to-child HIV transmission in the developing world -- reduces the risk of MTC HIV transmission in repeat pregnancies. The drug is given in pill form to HIV-positive women during labor to avoid MTC transmission and in syrup form to infants within 72 hours of birth (Kaiser Daily HIV/AIDS Report, 2/10/06).

According to the Times, the drug will cost 60 cents per patient daily in 78 low-income countries and $1.20 per patient daily in 67 middle-income countries. In developed countries, the drug costs between $10 and $14 per patient daily. The company also will waive a 5% royalty fee, reporting requirements and other existing obligations for generic drug producers that have World Health Organization approval to make nevirapine using voluntary licenses.

"We want to solve the problem (of access) once and for all," Banchi said, adding, "Preferential pricing is the only way how we can meet both conflicting needs in the fight against AIDS." The company "can refinance [its] high research and development costs for innovative, new treatments by the established price system in industrialized countries and can offer affordable medicines to patients in poor countries who otherwise cannot afford antiretroviral medication," Banchi said (Financial Times, 5/15).

"Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

View drug information on Viramune.





Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
FDA To Recommend That Doctors Conduct Genetic Screening Before Prescribing Antiretroviral Abacavir To Reduce Allergic Reactions
25 Jul 2008
FDA on Thursday is expected to issue an advisory that urges physicians to conduct genetic testing before prescribing GlaxoSmithKline's antiretroviral drug abacavir to reduce allergic reactions in people taking the drug, the...


Talking with Your Doctor image Talking with Your Doctor

Talking with your doctor can sometimes be difficult. Good health care, however, depends on an open dialogue between patients and doctors...

Keeping a Personal Medical Record image Keeping a Personal Medical Record

Medical information is usually scattered in many different places. To receive the best possible health care, people are encouraged to gather information in one place and create a personal medical record...

View more videos...